A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Liu, Zhongyu ^a   Zhang, Yingchong ^b   Niu, Yulong ^c   Li, Ke ^a   Liu, Xin ^a   Chen, Huijuan ^a   Gao, Chunfang ^a  

^a Central Hospital of PLA   (China)

^b Chengdu Municipal Center for Disease Control and Prevention   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; VASCULOTROPIN; BIOLOGICAL MARKER;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CASE CONTROL STUDY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GOLD STANDARD; HUMAN; META ANALYSIS; PROSPECTIVE STUDY; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; SERUM; SYSTEMATIC REVIEW; BLOOD; COLORECTAL NEOPLASMS; DATA MINING; PROGNOSIS; REPRODUCIBILITY; RISK; STATISTICAL MODEL;

BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; DATA MINING; HUMANS; LIKELIHOOD FUNCTIONS; ODDS RATIO; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84905644880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103910     Document Type: Review

References (77)

1. Parkin DM, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985.Int J Cancer 54:594-606. (Pubitemid 23188190)
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2006) Cancer statistics. CA Cancer J Clin 56: 106-130.
3. Chinacdc website. Available: http://www.chinacdc.cn/tjsj/gjwstjsj/201206/ W020120608368277572334.pdf. Accessed 2014 Jul 14.
4. Finlay IG, Pickford IR (1994) Colorectal carcinoma, in Lawson DH (ed): Current Medicine 4th edition, Edinburgh, Scotland, Churchill Livingstone pp: 51-64.
5. Cancer Res UK (2003) Cancer Stats Large - Bowel-UK4: 4-6.
6. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, et al. (2005) A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129: 422-428. (Pubitemid 41096630)
7. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, et al. (2012) Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 107: 1315-1329.
8. Ling BS, Moskowitz MA, Wachs D, Pearson B, Schroy PC (2001) Attitudes Toward Colorectal Cancer Screening Tests A Survey of Patients and Physicians. J Gen Intern Med 16: 822-830. (Pubitemid 34015697)
9. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, et al. (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348-1360. (Pubitemid 46874070)
10. Graziano F, Cascinu S (2003) Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: How much evidence is enough? Ann Oncol 14: 1026-1038. (Pubitemid 36950166)
11. Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, et al. (2003) Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9: 3700-3704. (Pubitemid 37169238)
12. Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J Clin Oncol 22: 529-536. (Pubitemid 41079782)
13. Allegra C, Sargent D (2003) Molecular diagnostics: Assays, tissues, progress, and pitfalls. J Clin Oncol 21: 395-396.
14. Deeks JJ, Altman DG, Bradburn MJ (2001) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman D, editors. Systematic Reviews in Health Care: Meta-analysis in context: BMJ Books. pp: 285-321.
15. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, et al. (2005) Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials 2: 209-217. (Pubitemid 40910470)
16. Van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA, et al. (2011) Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 104: 1325-1333.
17. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3: 25.
18. Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9:e1001216.
19. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
20. Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, et al. (2003) A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. Health Technol Assess 7: 1-162.
21. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
22. Centre for Reviews and Dissemination, University of York (2001) Undertaking systematic reviews of research on effectiveness: CRD's guidance for carrying out or commissioning reviews. Research Report. CRD Report (4 (2nd Edition)). NHS Centre for Reviews and Dissemination. UK: York.
23. Liu Z, Yao Z, Li C, Liu X, Chen H, et al. (2013) A step-by-step guide to the systematic review and meta-analysis of diagnostic and prognostic test accuracy evaluations. Br J Cancer 108: 2299-2303.
24. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6: 31.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
26. Harbord RM, Whiting P (2009) Meta-analysis of diagnostic accuracy using hierarchical logistic regression. In: Sterne JAC, editor. Meta-analysis in STATA: an updated collection from the STATA. Journa College Station. USA, 181-199.
27. Song F, Khan KS, Dinnes J, Sutton AJ (2002) Asymmetric funnel plots and publication bias in meta analyses of diagnostic accuracy. Int J Epidemiol 31: 88-95. (Pubitemid 34284907)
28. Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58: 882-893. (Pubitemid 41115772)
29. Rothstein HR, Sutton AJ, Borenstein M (2005) Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. Chichester, UK: Wiley.
30. Sterne JAC, Becker BJ, Egger M (2005) The Funnel Plot. In: Rothstein HR, Sutton AJ, Borenstein M, editors. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. Chichester, UK: Wiley. pp: 5-98.
31. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
32. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
33. Duval S, Tweedie R (2000) A nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. Journal of the American Statistical Association 95: 89-98.
34. Begg CB, Greenes RA (1983) Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 39: 207-215.
35. Bates AS, Margolis PA, Evans AT (1993) Verification bias in pediatric studies evaluating diagnostic tests. J Pediatr 122: 585-590. (Pubitemid 23093584)
36. Zhou XH (1998) Correcting for verification bias in studies of a diagnostic test's accuracy. Statistical Methods in Medical Research 7: 337-353.
37. Rutter CM, Gatsonis CA (2001) A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Statistics in Medicine 20: 2865-2884. (Pubitemid 32923212)
38. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, et al (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 58: 982-990. (Pubitemid 41316441)
39. Rutter CM, Gatsonis CA (2001) A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 20: 2865-2884. (Pubitemid 32923212)
40. Altman DG, Bland JM (1998) Time to event (survival) data. BMJ 317: 468-469.
41. Ransohoff DF, Feinstein AR (1978) Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 299: 926-930. (Pubitemid 9050459)
42. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, et al. (2004) Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 140: 189-202. (Pubitemid 38155650)
43. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, et al. (1997) Language bias in randomised controlled trials published in English and German. Lancet 350: 326-329. (Pubitemid 27351115)
44. Lijmer JG, Bossuyt PM, Heisterkamp SH (2002) Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 21: 1525-1537. (Pubitemid 34746061)
45. Glasziou PP, Sanders SL (2002) Investigating causes of heterogeneity in systematic reviews. Stat Med 21: 1503-1511. (Pubitemid 34746059)
46. Sica GT (2006) Bias in research studies. Radiology 238: 780-789.
47. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, et al. (1999) Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282: 1061-1066. (Pubitemid 29436454)
48. Westwood ME, Whiting PF, Kleijnen J (2005) How does study quality affect the results of a diagnostic meta-analysis? BMC Med Res Methodol 5: 20.
49. Vatn MH, Stalsberg H (1982) The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 49: 819-825. (Pubitemid 12165443)
50. Winawer SJ, Zauber A, Diaz B, O'Brien M, Gottlieb LS, et al. (1988) The National Polyp Study: overview of program and preliminary report of patient and polyp characteristics. Prog Clin Biol Res 279: 35-49.
51. Rex DK, Lehman GA, Ulbright TM, Smith JJ, Pound DC, et al. (1993) Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history. Am J Gastroenterol 88: 825-831. (Pubitemid 23181863)
52. Altman DG, Riley RD (2005) Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2: 466-472. (Pubitemid 41679099)
53. Keough-Ryan T, Hutchinson T, MacGibbon B, Senecal M (2002) Studies of prognostic factors in end-stage renal disease: an epidemiological and statistical critique. Am J Kidney Dis 39: 1196-1205. (Pubitemid 34591935)
54. Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144: 427-437. (Pubitemid 46768164)
55. Kyzas PA, Loizou KT, Ioannidis JP (2005) Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97: 1043-1055. (Pubitemid 41417921)
56. Clarke M (2008) Systematic review of reviews of risk factors for intracranial aneurysms. Neuroradiology 50: 653-664.
57. Smith V, Devane D, Begley CM, Clarke M, Higgins S (2007) A systematic review and quality assessment of systematic reviews of fetal fibronectin and transvaginal cervical length for predicting preterm birth. Eur J Obstet Gynecol Reprod Biol 133: 134-142. (Pubitemid 47069685)
58. Altman DG, De Stavola BL, Love SB, Stepniewska KA (1995) Review of survival analyses published in cancer journals. Br J Cancer 72: 511-518.
59. Fletcher RH (1986) Carcinoembryonic antigen. Ann. Int. Med 104: 66-73.
60. Duffy MJ (2001) CEA as a marker for colorectal cancer: is it clinically useful? Clin Chem 47: 624-630.
61. Goldstein MJ, Mitchell MJ (2005) Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23: 338-351. (Pubitemid 41656973)
62. Anonymous (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14: 2843-2877.
63. Bast RC, Ravdin P, Hayes DF, Bates B, Fritsche H, et al. (2001) Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878. (Pubitemid 32230890)
64. Klapdor R, Aronsson A-C, Duffy MJ, Hannson L-O, Khalifa R, et al. (1999) Tumor markers in gastrointestinal cancers: EGTM recommendations. Anticancer Res 119: 2811-2815.
65. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, et al. (2003) Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39: 718-727. (Pubitemid 36315986)
66. Grem J (1997) The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opinion Oncol 9: 380-387.
67. Duffy MJ (1998) CA 19-9, a marker for gastrointestinal cancers: a review. Ann Clin Biochem 35: 364-370.
68. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C (2002) CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 22: 2311-2316. (Pubitemid 34857058)
69. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Järvinen H, et al. (2004) CEA, CA 242, CA-19-9, CA 72-4 and hCGbin the diagnosis of recurrent colorectal cancer. Tumor Biol 25: 228-34. (Pubitemid 40082324)
70. Lindmark G, Bergstrom R, Pahlman L, Glimelius B (1995) The association of preoperative serum tumor markers with Dukes' stage and survival in colorectal cancer. Br J Cancer 71:1090-1094.
71. Nakayama T, Watababe M, Teramoto T, Kitajima M (1997) CA 19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol 66: 238-243. (Pubitemid 28013697)
72. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, et al. (2000) Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 5195-5198. (Pubitemid 32319106)
73. Nakayama T, Watababe M, Teramoto T, Kitajima M (1997) CA 19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol 66: 238-243. (Pubitemid 28013697)
74. Behbehani AI, Al-Sayer H, Farghaly M, Kanawati N, Mathew A, et al. (2000) Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait. Int J Biol Markers 15: 51-55. (Pubitemid 30195483)
75. Filella X, Molina R, Piquet JM, Garcia-Valdecasas JC, Grau JJ, et al. (1994) Use of CA 19-9 in the early detection of recurrences in colorectal cancer. Comparison with CEA. Tumor Biol 15: 1-6. (Pubitemid 24122938)
76. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, et al. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327. (Pubitemid 46631379)
77. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, et al. (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348-1360. (Pubitemid 46874070)